Modified Cytotoxicity Test Protocol for Mg Metals Developed for Class III Medical Devices
Wang Jiali,Qin Ling
DOI: https://doi.org/10.3389/conf.fbioe.2016.01.01256
IF: 5.7
2016-01-01
Frontiers in Bioengineering and Biotechnology
Abstract:Event Abstract Back to Event Modified cytotoxicity test protocol for Mg metals developed for class III medical devices Jiali Wang1* and Ling Qin1* 1 Chinese University of Hong Kong, Orthopaedics and Traumatology, Hong Kong, SAR China Introduction: Extensive preclinical study including in vitro and in vivo experiments have been performed in biodegradable Mg metal for its potential use as orthopaedic implants due to its positive contributions to new bone formation via promoting osteoblastic differentiation and angiogenesis[1]-[3]. More encouraging clinic outcomes have been reported in Germany, China and South Korea, greatly inspiring more and more clinicians and scientists to be involved in the R&D of Mg based medical devices[4]-[6]. However, in vitro cytotoxicity test, one critical step for the safety assurance of medical devices prior to the approval mandated from regulatory body, has been considered as the major factor inhibiting the product registration process of such novel implants due to low cell viability in Mg extracts (< 75%), which may be ascribed to limitations of ISO 10993 standards when applied for biodegradable metals. Optimized methods on extracts preparation and cytocompatibility assay have been proposed recently, aiming to facilitate the consistency of in vitro assessment data with in vivo biosafety evaluation results[7]-[9]. How to link in vitro and in vivo environment together for recommending a more reliable cytotoxicity testing protocol is still of a great challenge. Herein, we proposed a dilution of extracts for cytotoxicity assessment based on correlation establishment of in vitro and in vivo results after the critical factor in extracts affecting cell viability was found. Materials and Methods: Four cell types including BMSC, L-929 fibroblast, osteoblast and MC3T3-E1 were used for cytotoxicity test in pure Mg extracts and cell culture medium with a series of osmolality (300 to 600 mOsmol/kg), pH values (7.4 to 9.5) and Mg level (0.8 to 100 mM) adjusted by NaCl, NaOH and MgCl2 stock solution, respectively. In terms of in vivo study, pure Mg screws were inserted in bone marrow cavity of rabbits for 72 hours prior to pH, osmolality and Mg ion dose measurement in local bone marrow (or plasma) around implants. Results and Discussion: Mg dose in the extracts was the predominant factor contributing the cytotoxicity testing results. 10 mM and 15 mM were considered as the critical dose not adversely affecting cell viability and the biosafety level for the assurance of non-toxic risks with the lowest grade, respectively. After 72 hours implantation, very limited changes of pH, osmolality and Mg ion level were observed in local bone marrow, indicating that mismatch of in vitro and in vivo results was elicited by the huge gap between in vitro testing system and in vivo situation(Figure 1). So the in vitro tolerated Mg level (10-15 mM), in vivo maximal tolerated Mg range (3.5-5 mM) and real Mg level and biodegradation rates in in vitro cell culture medium and in vivo environment were used for calculation of a dilution factor of extracts prior to cytotoxicity tests, leading to a recommended a dilution range of 6 to 10 times for pure Mg implants. Conclusion: The recommended dilution range for the extracts to perform cytotoxicity evaluation was between 6 and 10. The significance of this work was to lay down a foundation for regulatory bodies to adopt our recommendation as the cell toxicity test protocol to be used for Mg-based medical devices. Hong Kong Collaborative Research Fund (Ref. CRF 2014/15-C4028-14GF); Guangdong Innovation Team Grant (Ref. 201001C0104669453)References:[1] Li Y, Liu G, Zhai Z, Liu L, Li H, Yang K, et al. Antimicrob Agents Chemother 2014.[2] Zhai WY, Lu HX, Wu CT, Chen L, Lin XT, Naoki K, et al. Acta Biomater 2013.[3] Yoshizawa S, Brown A, Barchowsky A, Sfeir C. Acta Biomater 2014.[4] Zhang X, Zhao DW, Wang B, Qin L. The 7th Biometal Conference. Italy2015.[5] Windhagen H, Radtke K, Weizbauer A, Diekmann J, Noll Y, Kreimeyer U, et al. Biomed Eng Online 2013.[6] Han HS, Seok HK, Kim YC. The 7th Biometal Conference. Italy2015.[7] Fischer J, Profrock D, Hort N, Willumeit R, Feyerabend F. Materials Science and Engineering B-Advanced Functional Solid-State Materials 2011.[8] Jung O, Smeets R, Porchetta D, Kopp A, Ptock C, Muller U, et al. Acta Biomater 2015.[9] Scheideler L, Fuger C, Schille C, Rupp F, Wendel HP, Hort N, et al. Acta Biomater 2013. Keywords: Implant, Biocompatibility, Biodegradable metal Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: New Frontier Oral Topic: Biomaterials to modulate biological processes involved in host response Citation: Wang J and Qin L (2016). Modified cytotoxicity test protocol for Mg metals developed for class III medical devices. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.01256 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. * Correspondence: Dr. Jiali Wang, Chinese University of Hong Kong, Orthopaedics and Traumatology, Hong Kong, Hong Kong, SAR China, Email1 Dr. Ling Qin, Chinese University of Hong Kong, Orthopaedics and Traumatology, Hong Kong, Hong Kong, SAR China, qin@ort.cuhk.edu.hk Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Jiali Wang Ling Qin Google Jiali Wang Ling Qin Google Scholar Jiali Wang Ling Qin PubMed Jiali Wang Ling Qin Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.